Anti-VEGF may treat CNV due to adult-onset foveomacular vitelliform dystrophy
Intravitreal ranibizumab maintained best corrected visual acuity and diminished central macular thickness in patients with choroidal neovascularization due to adult-onset foveomacular vitelliform dystrophy, according to a study.
Patients were followed for 12 months. Treatment was continued after the initial three monthly injections if necessary.
Twenty-one eyes lost fewer than three lines of visual acuity from baseline to final visit.
No significant change was found in BCVA from baseline to final visit; however, mean central macular thickness diminished significantly from baseline to final visit (327 µm vs. 260 µm, P = .001).